Comparison of four prognostic scores in peripheral T-cell lymphoma.

BACKGROUND: To compare the usefulness of four prognostic scores in patients with peripheral T-cell lymphoma (PTCL) from a single institution. PATIENTS AND METHODS: One hundred twenty-one patients (77 male/36 female, median age 53 years) with PTCL [anaplastic large-cell lymphoma (ALCL) 21, PTCL not otherwise specified 56 and other 44)]. Complete response (CR) rate and 5-year overall survival (OS) were 41% and 31%, respectively. International Prognostic Index (IPI), Prognostic Index for T-cell lymphoma (PIT), International peripheral T-cell lymphoma Project score (IPTCLP) and modified Prognostic Index for T-cell lymphoma (mPIT) were calculated as in the original references. mPIT was only assembled to 41 patients in whom Ki-67 immunostaining was available. ALCL patients were analyzed separately. RESULTS: Concordance among IPI, PIT and IPTCLP was 52% for low-risk group, 27% for low/intermediate-risk group, 20% for high/intermediate-risk group and 14% for high-risk group. IPI, PIT and IPTCLP predicted CR, with IPI being the best score in logistic regression. Neither Ki-67 immunostaining nor mPIT predicted CR. Five-year OS (low-risk versus intermediate- or high-risk categories) according to IPI, PIT, IPTCLP and mPIT were 52% versus 45%, 75% versus 49%, 58% versus 20% and 39% versus 0%, respectively. IPTCLP was the best score for OS in multivariate analysis. CONCLUSION: All the scores demonstrated their usefulness to assess the outcome of patients with PTCL, with IPTCLP being the most significant to predict OS.

Red-blood-cell alloimmunization and female sex predict the presence of HLA antibodies in patients undergoing liver transplant.

BACKGROUND: Refractoriness to platelet transfusion because of HLA antibodies can jeopardize the outcome of patients who require platelet support during surgery. As routine screening for HLA antibodies would pose a huge burden on presurgical work-ups, a stratification of patients according to the risk of having HLA antibodies is warranted. STUDY DESIGN AND METHODS: Clinical and laboratory data from 1351 patients submitted to liver transplant were analyzed to determine the accuracy of RBC alloimmunization and other patient features to predict the concomitant presence of HLA antibodies. Predictive variables were selected through binary logistic regression and their accuracy to prognosticate HLA alloimmunization was calculated by contingent table methods. RESULTS: RBC and HLA antibodies were detected in 70 (5·2%) and 71 (5·3%) patients, respectively. Female sex and RBC alloimmunization were the only patient features associated with HLA aloimmunization. Risk of being HLA immunized increased from male patients without RBC antibodies (n = 842; 1·5% with HLA antibodies) to female patients with RBC alloimmunization (n = 36, 36·2% with HLA antibodies), being of 9·7% in the remaining 473 patients. In women, the positive and negative predictive values of RBC alloimmunization to prognosticate HLA alloimmunization were 36% and 90%, respectively. In male patients, such values were 12% and 99%, respectively. The incidence of HLA immunization decreased after the introduction of universal leukoreduction in 2002. CONCLUSIONS: RBC alloimmunized female patients that may require platelet support during liver transplant should be preoperatively evaluated for HLA antibodies. Such evaluation is unnecessary in male patients without detectable RBC antibodies. Decision-making in the remaining patients must be individualized.